CAL
DMAC icon

Capital Analysts LLC’s DiaMedica Therapeutics DMAC Stock Holding History

Capital Analysts LLC’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7K Hold
1,050
– – ﹤0.01% 1311
2025
Q4 		$8K Buy
+1,050
New +$7.85K ﹤0.01% 1269

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital Analysts LLC's DMAC Position: Q1 2026 in Review

Capital Analysts LLC held its DiaMedica Therapeutics (DMAC) position steady in Q1 2026 at 1,050 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #1311.

Capital Analysts LLC first reported a position in DMAC in Q4 2025 and has held it in 2 quarters since. The position peaked at $8K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Capital Analysts LLC held 1,050 shares of DiaMedica Therapeutics worth $7K as of Q1 2026.
  • Capital Analysts LLC left its DiaMedica Therapeutics share count unchanged in Q1 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Capital Analysts LLC's portfolio in Q1 2026, its #1311 holding.
  • Capital Analysts LLC first reported a position in DiaMedica Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Capital Analysts LLC's DiaMedica Therapeutics position peaked at $8K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Capital Analysts LLC's 13F filing for Q1 2026, filed 14 May 2026.